6505--Notice of Intent to Award a Sole Source Procurement - Xofigo Radium-223 dichloride

The Department of Veterans Affairs, Veterans Health Administration, Veterans Integrated Service Network 17, intends to award a sole source firm-fixed price contract for the procurement of 660 units of Xofigo (Radium-223 dichloride), a pharmaceutical product. This procurement is being conducted under 41 U.S.C. 3304(a)(1) and FAR 6.302-1, allowing for non-competitive acquisition based on the determination that only one responsible source can satisfy agency requirements. While this notice is not a formal request for quotations or proposals, the VA will accept capability statements, proposals, or quotations from all responsible sources through December 19, 2025, at 2:00 PM Central Time to determine if comparable or more advantageous alternatives exist. The evaluation criteria will focus on whether alternative sources can provide equivalent products and services that would be more advantageous to the government. If no affirmative responses are received within 7 days of publication, the contract will be issued to the intended awardee without further notice.

This procurement carries no set-aside designation and is intended for Cardinal Health as the sole source contractor, based on a letter from Bayer Healthcare confirming that Cardinal Health is the only authorized U.S. distributor of Xofigo. The pricing for this procurement will be set by Bayer Healthcare, the manufacturer. Specific award values or budget ranges are not disclosed in this presolicitation notice. The procurement is categorized under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals), reflecting the medical pharmaceutical nature of the requirement. The contract is being managed by Network Contracting Office 17, located at the VA Central Texas Veterans Health Care System in Temple, Texas.